Organigram Holdings, Inc. (OTCQB: OGRMF), through its wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and Organigram is regulated by the Access to Cannabis for Medical Purposes Regulations.
Adult recreational use of cannabis in Canada is expected to be legalized in the summer of 2018. The company’s shares have jumped over 40% since April as the legalization date draws nearer.
__________________________________________________________________
Welcome to Traders News Source,
Stay tuned and keep an eye on your inbox for our next hot Small-Mid Cap stock report coming soon.
We have an outstanding track record for near-term gains in the Small Cap arena.
Do not forget to add us to your preferred/safe senders list within your email service provider. Expect one new Small Cap NASDAQ or NYSE listed company research report per week free of charge.
We only alert you to stocks we believe will offer up near-term trading profits.
Receive TEXT ALERTS the minute we initiate coverage
Text the word “Traders” to the number “25827” from your cell phone to receive small cap reports in real-time ahead of the crowd.
Update – We will be initiating coverage on an exciting NASDAQ small cap growth stock sporting a tiny float within the next few days!
____________________________________________________________________
Recent Events
May 24, 2018. Organigram Holdings announced that it has entered into a letter of intent with Hyasynth Biologicals, Inc. whereby Organigram proposes to make a strategic investment in Hyasynth. Additionally, the non-binding letter of intent contemplates Organigram entering into an off-take agreement with Hyasynth whereby Organigram can purchase a pre-defined quantity of a range of cannabinoids or cannabinoid related production from Hyasynth on terms set forth in such agreement. https://www.otcmarkets.com/stock/OGRMF/news/Organigram-Announces-Letter-of-Intent-for-Strategic-Investment-in-Hyasynth-Biologicals-Inc?id=193452
May 17, 2018 /CNW/ – Organigram announced that it has received a “Permit to Export Cannabis” from Health Canada that will allow the Company to begin its first international shipments. Organigram will now be able to ship dried cannabis products to Cannatrek Medical PTY Ltd, a licensed Australian medical cannabis enterprise with operations in Melbourne, Victoria through its broker Cannada Management Group Global Inc., a leading global cannabis and hemp brokerage firm for import/export, procurement and logistics of cannabis and hemp related products. https://www.otcmarkets.com/stock/OGRMF/news/Organigram-Receives-Permit-to-Export-Medical-Cannabis-to-Australia?id=192741
May 15, 2018. Organigram unveiled their Phase 1 branding strategy for the adult recreational market in Canada. Organigram’s unprecedented recreational portfolio will be officially launched once adult use recreational cannabis is legal in Canada and includes the launch of The Edison Cannabis Company, ANKR Organics and Trailer Park Buds. “Our recreational brand strategy incorporates the best of what we know about our current and potential customers, the industry and opportunities for growth, and the production of our premium products,” says Greg Engel, CEO, Organigram. “The addition of each of these brands is the result of more than 18 months of research, development and teamwork to better understand our products and consumers.” https://www.otcmarkets.com/stock/OGRMF/news/Organigram-Unveils-Comprehensive-Suite-of-Adult-Recreational-Cannabis-Brands?id=192395
Products
A premium product, The Edison Cannabis Company will offer dried cannabis, pre-rolled and cannabis oil products across Canada at the advent of adult recreational use in 2018. Mined from a comprehensive research project that included the launch of ‘The Edison Project by OGI’ in November 2017, the Edison brand was founded on the ceaseless pursuit of improvement and innovation at Organigram.
The marquee sub-brand offered within the Edison family is Edison Reserve, a line of products that represents the best quality indoor grown product in the country. Edison Reserve product will only be available in larger pack sizes of dried flower, and will feature the Company’s top bud, hand manicured and craft cured for optimal consumer experience.
Organigram is Canada’s original organic cultivator; the subsequent progress and quality of product exists in the DNA of ANKR Organics. As a result of several years of research related to perfecting the art of organic cannabis cultivation and an ongoing partnership with a governing body, Organigram is poised to offer consumers the best quality organically-grown cannabis in the country. The Company continues to finalize plans for organic certification, which is planned for later in 2018.
Through an existing partnership with Trailer Park Productions, Organigram is proud to introduce Trailer Park Buds, a cannabis brand with a wink that speaks to consumers who appreciate a sense of humor and don’t take themselves too seriously. Focused on a value-conscious consumer who appreciates quality product, pre-rolled and blended products will be available at federally-licensed retail establishments across Canada in 2018.
Since 2014, Organigram has existed to help improve the lives of its patients through the federally-regulated medical cannabis system. Since that time, Organigram has grown to stand for a holistic approach to health focused on the pillars of quality, compassion, trust and consistency. Organigram will remain the Company’s primary medical brand.
About
Organigram Holdings Inc. is a company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
Financial review
The company has a FYE of August 31st.
Q2 ending 2/28/2018
Total Revenue 3,688.773
Cost of Revenue -2,834.023
Gross Profit 6,522.796
Operating Expenses
Selling General and Administrative 3,148.703
Total Operating Expenses 1,468.305
Operating Income or Loss 2,220.468
Income from Continuing Operations
Total Other Income/Expenses Net -1,142.782
Earnings Before Interest and Taxes 2,220.468
Interest Expense -1,429.015
Income Before Tax 1,077.686
Net Income 1,077.686
Outlook
Phase 3 expansion expected to be complete for the start of filling of rooms with first cannabis plants by June 1, 2018 bringing the Company’s pro-forma run-rate capacity to 36,000 kg/yr;
The Company intends to launch its adult-recreational brand strategy on or about May 15, 2018; and Organigram expects to announce one or more strategic or international investments in the upcoming quarter.
Stock influences and risk factors
The adult recreational use of cannabis in Canada, expected to be legalized in the summer of 2018, may act as a catalyst for company shares;
The most recent quarter was profitable, but the company has a history of losses;
The company may have to raise capital in the future for operations and/or acquisitions and such capital raises could be dilutive.
Stock chart
On Wednesday, May 30, 2018, OGRMF shares were at $3.90 on traded volume of 202K shares. The current RSI is 65.88
At $3.90 OGRMF shares are trading above their 50 DMA and 200 DMA of $3.59 and $2.93 respectively.
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
